Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor

被引：0
|
作者：
Simon J. B. Aylwin
Istvan Bodi
Ronald Beaney
机构：
[1] King’s College Hospital,Department of Endocrinology
[2] King’s College Hospital,Department of Clinical Neuropathology
[3] Guy’s & St Thomas’ Hospital Cancer Centre,Department of Neuro
来源：
Pituitary | 2016年 / 19卷
关键词：
Vemurafenib; Craniopharyngioma; Prolactinoma; BRAF Inhibitor; BRAF V600E Mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：544 / 546
页数：2
相关论文
共 50 条
  • [31] Erythema nodosum, an uncommon cutaneous side effect of the BRAF inhibitor, Vemurafenib
    Robinson, D.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2013, 54 : 16 - 16
  • [32] BRAF inhibitor (vemurafenib) resistance confers sensitivity to arginine deprivation in melanoma
    Li, Ying-Ying
    Wu, Chunjing
    Chen, Shu-Mei
    Wangpaichitr, Medhi
    You, Min
    Spector, Seth
    Feun, Lynn G.
    Kuo, Macus T.
    Savaraj, Niramol
    CANCER RESEARCH, 2014, 74 (19)
  • [33] BRAF-V600E MUTANT PAPILLARY CRANIOPHARYNGIOMA DRAMATICALLY RESPONDS TO COMBINATION BRAF AND MEK INHIBITORS
    Roque, Ashley
    Odia, Yazmin
    NEURO-ONCOLOGY, 2016, 18 : 162 - 162
  • [34] A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib
    Zhu, You-cai
    Wang, Wen-xian
    Xu, Chun-wei
    Zhuang, Wu
    Du, Kai-qi
    Chen, Gang
    Lv, Tang-feng
    Song, Yong
    CLINICAL LUNG CANCER, 2019, 20 (03) : E224 - E228
  • [35] BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response
    Tan, Serena
    Pollack, Jonathan R.
    Kaplan, Michael J.
    Colevas, A. Dimitri
    West, Robert B.
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2016, 122 (01): : E5 - E7
  • [36] Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib
    Gavric, Ana Ursula
    Ocvirk, Janja
    Mekjavic, Polona Jaki
    RADIOLOGY AND ONCOLOGY, 2018, 52 (02) : 213 - 219
  • [37] The role of BRAF testing of Rathke's cleft cysts to identify missed papillary craniopharyngioma
    Candy, Nicholas G.
    Mignone, E.
    Quick, E.
    Koszyca, B.
    Brown, A.
    Chapman, I. M.
    Torpy, D. J.
    Vrodos, N.
    Santoreneos, S.
    De Sousa, S. M. C.
    PITUITARY, 2025, 28 (01)
  • [38] Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature
    Losa, M.
    Mazza, E.
    Pedone, E.
    Nocera, G.
    Liscia, N.
    Reni, M.
    Mortini, P.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024, 47 (11) : 2835 - 2842
  • [39] The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
    Kim, Alex
    Cohen, Mark S.
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (09) : 907 - 916
  • [40] Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma
    Luke, Jason J.
    Hodi, F. Stephen
    CLINICAL CANCER RESEARCH, 2012, 18 (01) : 9 - 14
12345